{"meta":{"query_hash":"ead79cb73d79","filters":{"venue":"Immunotherapy Advances"},"cohort_total":7,"direct_labels_cover":0,"predictions_cover":7,"exported":7,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/ead79cb73d79","api":"https://metacan.xera.ac/api/v1/cohort?venue=Immunotherapy+Advances"},"results":[{"id":"W3215895013","doi":"10.1093/immadv/ltab022","title":"A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes","year":2021,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Calgary","funders":"Breakthrough T1D Canada; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Versus Arthritis; Diabetes UK; Leona M. and Harry B. Helmsley Charitable Trust; National Institute for Health and Care Research; Immune Tolerance Network; Innovative Medicines Initiative; BC Children's Hospital","keywords":"Medicine; Dosing; Internal medicine; Cohort; Maintenance therapy; Type 1 diabetes; Adverse effect; Type 2 diabetes; Clinical endpoint; Cmax; Gastroenterology; Immunology; Diabetes mellitus; Pharmacokinetics; Endocrinology; Randomized controlled trial; Chemotherapy","score_opus":0.01257137853055862,"score_gpt":0.3053642460621322,"score_spread":0.2927928675315736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215895013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98480564,0.013928625,0.00000738816,0.000019200186,0.00010999388,0.0003315653,0.000011604706,0.0000064992623,0.0007795051],"genre_scores_gemma":[0.9974926,0.0017946594,0.00028563786,0.000075267264,0.000019363939,0.000045054825,0.000058222828,0.000026600103,0.00020259626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990023,0.000076080236,0.00023336717,0.0003219988,0.00011922557,0.00024703116],"domain_scores_gemma":[0.999423,0.000017228984,0.00014692746,0.00027776128,0.00011174073,0.000023322234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117538344,0.00015351246,0.0002511841,0.000039182156,0.000055547214,0.00004402568,0.0002622136,0.000059437913,0.000021338241],"category_scores_gemma":[0.000031055817,0.00013465561,0.00002369556,0.00031317057,0.000040001512,0.000022492157,0.000073923475,0.00007406712,0.0000010998472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022793906,0.017454756,0.1159782,0.000051936513,0.0005307053,0.000020050447,0.0018441861,0.00012808097,0.74842703,0.000018030913,0.000052081654,0.11321553],"study_design_scores_gemma":[0.26485825,0.03539496,0.020174026,0.000865022,0.00010770129,0.000009699258,0.032964613,0.00018184187,0.61872,0.00025271726,0.024594175,0.0018769713],"about_ca_topic_score_codex":0.00006198848,"about_ca_topic_score_gemma":0.0010231588,"teacher_disagreement_score":0.26257887,"about_ca_system_score_codex":0.000012892186,"about_ca_system_score_gemma":0.000077581164,"threshold_uncertainty_score":0.54910964},"labels":[],"label_agreement":null},{"id":"W4408363348","doi":"10.1093/immadv/ltaf006","title":"Development and evaluation of two whole-blood flow cytometry protocols for monitoring patients treated with JAK inhibitors","year":2024,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada","keywords":"Flow cytometry; Phosphorylation; STAT5; Cytokine; stat; Biology; Immunology; STAT3; Molecular biology; Cell biology; Cancer research","score_opus":0.039189128658499606,"score_gpt":0.3721557140798626,"score_spread":0.332966585421363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408363348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99019974,0.0027250769,0.00058295816,0.000028061177,0.00013377253,0.006167496,0.000017472568,0.0000522417,0.00009316839],"genre_scores_gemma":[0.9801818,0.000046734593,0.013675496,0.000009541588,0.00012669523,0.0058212434,0.00003842684,0.000031844298,0.000068233414],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990929,0.000019237625,0.00026624417,0.00019533714,0.00030968036,0.00011661889],"domain_scores_gemma":[0.9994276,0.00006017863,0.00007904196,0.000105553474,0.0002994895,0.000028120372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022967144,0.00012583124,0.00018484636,0.0001619664,0.00006986073,0.00003252507,0.000030196605,0.000027450182,0.000017822522],"category_scores_gemma":[0.000022309781,0.00008983995,0.000041416446,0.00021472579,0.000030112367,0.00021572773,0.0000056569816,0.0000718308,0.000001126633],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007305811,0.00030869571,0.034473035,0.0002884689,0.0003221233,0.0000013803141,0.0011050508,0.00010533745,0.3874818,0.000009259357,0.000012332691,0.57516193],"study_design_scores_gemma":[0.006580465,0.0012621946,0.008422387,0.0024143916,0.00013567938,0.0000084039775,0.00014518452,0.00063608534,0.94043255,0.000029318428,0.039789967,0.00014335748],"about_ca_topic_score_codex":0.0000064255323,"about_ca_topic_score_gemma":0.0000026500798,"teacher_disagreement_score":0.5750186,"about_ca_system_score_codex":0.00006706226,"about_ca_system_score_gemma":0.00012090563,"threshold_uncertainty_score":0.3663567},"labels":[],"label_agreement":null},{"id":"W4408970497","doi":"10.1093/immadv/ltaf010","title":"Abnormal glucose and lipid metabolism promotes disrupted differentiation of T and B cell subsets in Behçet’s disease","year":2024,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Ocular Diseases and Behçet’s Syndrome","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Natural Science Foundation of Shandong Province; National Natural Science Foundation of China","keywords":"Immune system; Immune dysregulation; Immunology; CD8; T cell; Dendritic cell; Flow cytometry; Biology; Pathogenesis; Cytotoxic T cell; In vitro","score_opus":0.0065555307667504534,"score_gpt":0.26065858318566415,"score_spread":0.2541030524189137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408970497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77062666,0.22852723,0.00008402386,0.0002300871,0.00012321622,0.0002952702,0.000041021427,0.000035354275,0.000037100293],"genre_scores_gemma":[0.97736627,0.022095142,0.00019372806,0.000043971435,0.000056860976,0.000027806786,0.000059617716,0.000025070853,0.00013154761],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990743,0.00003811296,0.00026056395,0.0002711235,0.00017812611,0.00017779664],"domain_scores_gemma":[0.9995936,0.00004741999,0.00005646647,0.00016933547,0.00002811308,0.000105025516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008711276,0.00016757862,0.00029553313,0.0001524223,0.000034784065,0.00004195753,0.00004630962,0.000042903142,0.00009535433],"category_scores_gemma":[0.000014439397,0.00012950382,0.00007580034,0.00017525612,0.00010247131,0.00033262942,0.000022956792,0.00010011823,0.0000019925458],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024708835,0.0015420099,0.22973299,0.0036014842,0.000310135,0.00028134216,0.0023707254,0.000016462629,0.33973086,0.00064111094,0.00001945948,0.41928256],"study_design_scores_gemma":[0.003056632,0.00026774278,0.9664256,0.00060787774,0.00022056783,0.000030430952,0.00012423532,0.0013437105,0.017574348,0.0009129987,0.0091567235,0.00027915186],"about_ca_topic_score_codex":0.000029428931,"about_ca_topic_score_gemma":0.000012121343,"teacher_disagreement_score":0.7366926,"about_ca_system_score_codex":0.000013996584,"about_ca_system_score_gemma":0.00004616313,"threshold_uncertainty_score":0.52810127},"labels":[],"label_agreement":null},{"id":"W4413772343","doi":"10.1093/immadv/ltaf029","title":"CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis","year":2024,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; University of Southampton; Cancer Research UK; Leukaemia UK; National Institute for Health and Care Research; Wessex Medical Research","keywords":"Antibody-dependent cell-mediated cytotoxicity; Interleukin 15; Immunology; Chemistry; Cell biology; Cytokine; Interleukin; Medicine; Biology; Antibody","score_opus":0.013867831947297888,"score_gpt":0.3156228466059725,"score_spread":0.3017550146586746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413772343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7590446,0.23194575,0.0016466067,0.0014617598,0.0006898471,0.0011350552,0.000090017784,0.0003053083,0.0036810539],"genre_scores_gemma":[0.94089824,0.053967748,0.0003818484,0.0006260246,0.00035145282,0.00009447779,0.00006566863,0.00009923969,0.0035153152],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716026,0.00016293788,0.0004615442,0.00068366824,0.0008444356,0.0006871446],"domain_scores_gemma":[0.9980786,0.00078884227,0.000082124614,0.00083044823,0.00009937384,0.00012064274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000487707,0.00038090974,0.00048180134,0.000110557674,0.00026641026,0.00020601414,0.00040789208,0.00017147815,0.00059667975],"category_scores_gemma":[0.000074039315,0.00024272755,0.00017413984,0.00045898338,0.00058122794,0.0004908884,0.00013538898,0.00059722346,0.00017009374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009707562,0.00026644682,0.00024031979,0.0011063471,0.00043453753,0.00082122284,0.005369179,0.000069394286,0.97483325,0.00044325835,0.0010002154,0.014445077],"study_design_scores_gemma":[0.01020456,0.00063402695,0.00030232873,0.0005135514,0.00009209271,0.000381116,0.001330024,0.0043810485,0.56244814,0.0012415142,0.41795874,0.0005128179],"about_ca_topic_score_codex":0.000611835,"about_ca_topic_score_gemma":0.000024353278,"teacher_disagreement_score":0.41695854,"about_ca_system_score_codex":0.0014908961,"about_ca_system_score_gemma":0.0013342662,"threshold_uncertainty_score":0.9898142},"labels":[],"label_agreement":null},{"id":"W7141300528","doi":"10.1093/immadv/ltaf031","title":"Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort study","year":2025,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Nivolumab; Atezolizumab; Pembrolizumab; Hazard ratio; Ipilimumab; Overall survival; Proportional hazards model; Baseline (sea); Biomarker","score_opus":0.0046702480945134735,"score_gpt":0.2520719266116027,"score_spread":0.24740167851708925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7141300528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773009,0.01699409,0.000081923274,0.00024981075,0.00046020176,0.004594462,0.00005809384,0.00011826621,0.00014225805],"genre_scores_gemma":[0.99679613,0.0017397904,0.00012503465,0.00007598099,0.000053160005,0.0007860029,0.000113079295,0.00006360454,0.00024719743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702245,0.00028958073,0.0009854772,0.00068713655,0.0005256995,0.000489634],"domain_scores_gemma":[0.99851394,0.00018039411,0.000425272,0.000566046,0.00023678309,0.00007755884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060831,0.0005225569,0.0008467113,0.00029687508,0.00017426418,0.000060717633,0.00013570926,0.00012049683,0.000059412363],"category_scores_gemma":[0.00008648226,0.0004067928,0.000111923924,0.0004187242,0.00008589385,0.00038713645,0.000049146158,0.00021236029,0.00000274297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009381423,0.0025137062,0.92252576,0.00020667523,0.00072825945,0.000015878195,0.0007533187,0.00008189229,0.010855473,0.0000046933174,0.00000954435,0.05292335],"study_design_scores_gemma":[0.029874695,0.001360673,0.94836956,0.0032724368,0.00015255348,0.0000011453532,0.0010151425,0.00013331065,0.0135365315,0.000011280361,0.0018129776,0.00045966057],"about_ca_topic_score_codex":0.00015424262,"about_ca_topic_score_gemma":0.00021032499,"teacher_disagreement_score":0.05246369,"about_ca_system_score_codex":0.0011855209,"about_ca_system_score_gemma":0.00015804324,"threshold_uncertainty_score":0.9998384},"labels":[],"label_agreement":null},{"id":"W7147334668","doi":"10.1093/immadv/ltaf038","title":"Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells <i>in vitro</i>","year":2025,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"CD28; T-cell receptor; Cytotoxic T cell; Chimeric antigen receptor; Antigen; Effector; Streptamer; Signal transduction; Jurkat cells","score_opus":0.015110604342451496,"score_gpt":0.30191830494043137,"score_spread":0.2868077005979799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7147334668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94647014,0.04904118,0.0024550683,0.00023834554,0.0003600529,0.000885364,0.000005959098,0.00007234754,0.00047152356],"genre_scores_gemma":[0.957327,0.039588153,0.001051579,0.000085394546,0.0001239662,0.00005477454,0.000015209878,0.000045615674,0.0017083165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980705,0.00010594326,0.00055081287,0.00053334417,0.0003391381,0.00040028626],"domain_scores_gemma":[0.9991052,0.00012894873,0.00015729279,0.00042060832,0.00013754683,0.00005040276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052738335,0.00026408865,0.0005970307,0.00044039995,0.00013802732,0.000027632734,0.00015478545,0.00009562122,0.00013449778],"category_scores_gemma":[0.000027844355,0.00025401742,0.00010131546,0.0007116862,0.0002049776,0.00023141743,0.000029271947,0.0003522184,0.0000022545503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013655149,0.00013627474,0.00048495748,0.00012034351,0.000069941,0.0000072240696,0.0010894163,0.00022996006,0.85177666,0.0000426141,0.000010365676,0.14466672],"study_design_scores_gemma":[0.0016001479,0.0003944313,0.001963606,0.0005686674,0.0000069502353,0.00000585311,0.0005926897,0.00021653864,0.98385954,0.00009575941,0.0105022695,0.00019355788],"about_ca_topic_score_codex":0.000050176764,"about_ca_topic_score_gemma":0.000010914817,"teacher_disagreement_score":0.14447317,"about_ca_system_score_codex":0.000110447305,"about_ca_system_score_gemma":0.00008050163,"threshold_uncertainty_score":0.9999912},"labels":[],"label_agreement":null},{"id":"W7163193919","doi":"10.1093/immadv/ltag010","title":"NLRC5 expression within tumor cells is critical to activate adaptive and innate antitumor immune responses","year":2025,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Downregulation and upregulation; Immune system; Melanoma; Tumor microenvironment; Antigen presentation; Autophagy; Antigen; Acquired immune system","score_opus":0.01005255377483979,"score_gpt":0.2931361700015136,"score_spread":0.28308361622667383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7163193919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83401364,0.15670398,0.0021559205,0.0024488007,0.00236881,0.00089881045,0.00014842035,0.00027045878,0.0009911744],"genre_scores_gemma":[0.97862726,0.00474818,0.0020757706,0.0046236077,0.000030323821,0.00017871917,0.000012555196,0.00007115848,0.009632394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99676806,0.00077072607,0.00081191194,0.0007832444,0.000106607775,0.00075946166],"domain_scores_gemma":[0.99758077,0.0012092827,0.0002246198,0.00076590123,0.00017643582,0.000042986765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055975845,0.00057005254,0.00078158994,0.0005225869,0.00080518005,0.00011010666,0.00058453984,0.00024781545,0.0005906491],"category_scores_gemma":[0.00027093076,0.000487351,0.00018334262,0.0004996865,0.0008223641,0.0006776564,0.00020386215,0.000582437,0.00021083542],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017356612,0.00021636143,0.00018704608,0.0000414145,0.00023224484,0.000015201935,0.0015846473,0.0000075034327,0.95585215,0.00149653,0.0006147405,0.02239556],"study_design_scores_gemma":[0.00203844,0.0006732767,0.0020582438,0.00047522885,0.000022381178,0.0000455577,0.0015149458,0.0000028602556,0.80868536,0.0007891974,0.18323763,0.00045686253],"about_ca_topic_score_codex":0.000103199316,"about_ca_topic_score_gemma":0.0000056709196,"teacher_disagreement_score":0.1826229,"about_ca_system_score_codex":0.000076582335,"about_ca_system_score_gemma":0.00019829524,"threshold_uncertainty_score":0.9997578},"labels":[],"label_agreement":null}]}